Bryce Point Capital LLC Invests $448,000 in 10x Genomics, Inc. (NASDAQ:TXG)

Bryce Point Capital LLC acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 31,215 shares of the company’s stock, valued at approximately $448,000.

Other large investors also recently modified their holdings of the company. Signaturefd LLC grew its holdings in 10x Genomics by 424.6% during the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock worth $26,000 after acquiring an additional 1,452 shares during the period. Blue Trust Inc. grew its stake in 10x Genomics by 73.1% during the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock worth $44,000 after purchasing an additional 1,299 shares during the period. Sound Income Strategies LLC increased its holdings in 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after purchasing an additional 1,330 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in 10x Genomics in the fourth quarter valued at approximately $52,000. Finally, SRS Capital Advisors Inc. boosted its holdings in shares of 10x Genomics by 817.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company’s stock worth $70,000 after buying an additional 4,324 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TXG has been the topic of a number of research reports. Canaccord Genuity Group dropped their target price on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Barclays cut their price objective on shares of 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. JPMorgan Chase & Co. decreased their target price on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. Leerink Partners cut 10x Genomics from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $25.00 to $12.00 in a research note on Thursday, February 13th. Finally, Morgan Stanley lowered their target price on 10x Genomics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $20.21.

10x Genomics Trading Down 6.3 %

Shares of 10x Genomics stock opened at $7.47 on Friday. The business’s fifty day simple moving average is $11.41 and its 200 day simple moving average is $14.66. 10x Genomics, Inc. has a 12 month low of $7.19 and a 12 month high of $37.74. The firm has a market capitalization of $913.60 million, a P/E ratio of -4.91 and a beta of 1.93.

10x Genomics (NASDAQ:TXG) last released its earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling at 10x Genomics

In other news, Director Alan Mateo purchased 40,000 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were purchased at an average price of $11.14 per share, with a total value of $445,600.00. Following the transaction, the director now directly owns 61,691 shares of the company’s stock, valued at approximately $687,237.74. This represents a 184.41 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Benjamin J. Hindson sold 4,573 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the transaction, the insider now owns 335,324 shares of the company’s stock, valued at $3,712,036.68. The trade was a 1.35 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 10.03% of the company’s stock.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.